Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine.
about
Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.Development of replication-competent viral vectors for HIV vaccine delivery.Nonhomologous recombination between defective poliovirus and coxsackievirus genomes suggests a new model of genetic plasticity for picornavirusesCurrent progress in the development of a prophylactic vaccine for HIV-1.Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinantsIntranasal delivery of vaccines against HIV.Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.Use of viral vectors for the development of vaccines.Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector.Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses.Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.CD34+ hematopoietic stem cells support entry and replication of poliovirus: a potential new gene introduction route.Human Rhinovirus-A1 as an Expression Vector.Sindbis virus with a tricomponent genomeCharacterization of the rheological, mucoadhesive, and drug release properties of highly structured gel platforms for intravaginal drug delivery.Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development
P2860
Q33686890-526D1706-FD88-4B56-96C7-9CB21D9FE3BDQ33694226-414E6024-2F09-477C-B7B2-3497DD17C8EFQ34026234-B06B1A94-A854-4675-858D-F4FF83514143Q34502108-5BF90B82-9B70-4E1A-AEED-4970F32DA482Q35973518-FB9CCE4E-808B-4923-B339-8D245A0B30ACQ36409054-26A352C3-EFEB-41ED-A3B2-A68810F6EDBDQ36780136-474FA510-D25F-47CB-B7E5-AD60BE7A2F09Q36780156-E9485363-19B6-4729-8B30-6BCEF93DD6FAQ37340465-819610AA-BED9-4F48-AD20-7E7881D60E79Q37349966-013EC487-0982-45F8-8A32-CBCCE5EF8C10Q37419985-98A29D67-BED9-46C0-8C2B-53FFECF5520FQ37806749-319891F5-BD6B-40E8-B724-F2E64F9564A5Q39197846-C77AB3B4-B696-4EAD-9510-04E28CEB5804Q40259597-AC862B3F-99F2-4C1F-A291-ECF172752CE3Q40481046-DC053CC6-C535-4718-8D0B-935F129D2697Q42007878-FA0020A1-992A-4D93-8D71-6277F9378C1DQ56993265-8255F520-3DC9-4743-9765-3E008FA25A52
P2860
Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Poliovirus vaccine strains as ...... se to develop an AIDS vaccine.
@ast
Poliovirus vaccine strains as ...... se to develop an AIDS vaccine.
@en
type
label
Poliovirus vaccine strains as ...... se to develop an AIDS vaccine.
@ast
Poliovirus vaccine strains as ...... se to develop an AIDS vaccine.
@en
prefLabel
Poliovirus vaccine strains as ...... se to develop an AIDS vaccine.
@ast
Poliovirus vaccine strains as ...... se to develop an AIDS vaccine.
@en
P1476
Poliovirus vaccine strains as ...... se to develop an AIDS vaccine.
@en
P2093
Raul Andino
Shane Crotty
P304
P356
10.1016/J.ADDR.2003.10.042
P407
P577
2004-04-01T00:00:00Z